Chemical Biology Drug Sensitivity Screen Identifies Sunitinib as Synergistic Agent with Disulfiram in Prostate Cancer Cells

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Ketola, Kirsi ^a   Kallioniemi, Olli ^b   Iljin, Kristiina ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

5 ALPHA ANDROSTANE 3 ALPHA 17 BETA DIOL; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANDROSTENEDIONE; ANDROSTERONE; ANTIOXIDANT; ASTAXANTHIN; BORTEZOMIB; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; CETUXIMAB; CGP 74514A; CYCLIN DEPENDENT KINASE INHIBITOR 1; DEQUALINIUM; DISULFIRAM; DNA TOPOISOMERASE INHIBITOR; EPIRUBICIN; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; THREO 1 PHENYL 2 DECANOYLAMINO 3 MORPHOLINO 1 PROPANOL; TYRPHOSTIN; TYRPHOSTIN AG 528; UNCLASSIFIED DRUG; UVOMORULIN; VINORELBINE DITARTRATE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL CULTURE; CELL INVASION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SCREENING; DRUG SENSITIVITY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SPHEROID CELL; WESTERN BLOTTING;

APOPTOSIS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DISULFIRAM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDOLES; MALE; NEOPLASM INVASIVENESS; ONCOGENE PROTEINS, FUSION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PYRROLES; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84871226233     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051470     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61 (2):: 69-90. 10.3322/caac.20107.
2. Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, et al. (2009) High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res 15 (19):: 6070-6078. 10.1158/1078-0432.CCR-09-1035.
3. Platz EA, Yegnasubramanian S, Liu JO, Chong CR, Shim JS, et al. (2011) A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Online First April 3, 2011.
4. Lin J, Haffner MC, Zhang Y, Lee BH, Brennen WN, et al. (2011) Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate 71 (4)():: 333-343. 10.1002/pros.21247.
5. Wang W, McLeod HL, Cassidy J, (2003) Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 104 (4):: 504-511. 10.1002/ijc.10972.
6. Morrison BW, Doudican NA, Patel KR, Orlow SJ, (2010) Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma. Melanoma Res 20 (1):: 11-20. 10.1097/CMR.0b013e328334131d.
7. Wickstrom M, Danielsson K, Rickardson L, Gullbo J, Nygren P, et al. (2007) Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients. Biochem Pharmacol 73 (1):: 25-33. 10.1016/j.bcp.2006.08.016.
8. Yakisich JS, Siden A, Eneroth P, Cruz M, (2001) Disulfiram is a potent in vitro inhibitor of DNA topoisomerases. Biochem Biophys Res Commun 289 (2):: 586-590. 10.1006/bbrc.2001.6027.
9. Sauna ZE, Shukla S, Ambudkar SV, (2005) Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections. Mol Biosyst 1 (2):: 127-134. 10.1039/b504392a.
10. Brar SS, Grigg C, Wilson KS, Holder WD Jr, Dreau D, et al. (2004) Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. Mol Cancer Ther 3 (9):: 1049-1060.
11. Lovborg H, Oberg F, Rickardson L, Gullbo J, Nygren P, et al. (2006) Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram. Int J Cancer 118 (6):: 1577-1580. 10.1002/ijc.21534.
12. Ketola K, Vainio P, Fey V, Kallioniemi O, Iljin K, (2010) Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells. Mol Cancer Ther 9 (12):: 3175-3185. 10.1158/1535-7163.MCT-10-0368.
13. Yip NC, Fombon IS, Liu P, Brown S, Kannappan V, et al. (2011) Disulfiram modulated ROS-MAPK and NFkappaB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer 104 (10):: 1564-1574. 10.1038/bjc.2011.126.
14. Alison MR, Lin WR, Lim SM, Nicholson LJ, (2012) Cancer stem cells: In the line of fire. Cancer Treat Rev. 10.1016/j.ctrv.2012.03.003.
15. Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, et al. (2001) VCaP, a cell-based model system of human prostate cancer. In Vivo 15 (2):: 163-168.
16. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
17. Gotink KJ, Verheul HM, (2010) Anti-angiogenic tyrosine kinase inhibitors: What is their mechanism of action? Angiogenesis 13 (1):: 1-14. 10.1007/s10456-009-9160-6.
18. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, et al. (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27 (22):: 3584-3590. 10.1200/JCO.2008.20.1293.
19. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368 (9544):: 1329-1338. 10.1016/S0140-6736(06)69446-4.
20. Papaetis GS, Syrigos KN, (2009) Sunitinib: A multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 23 (6)():: 377-389. 10.2165/11318860-000000000-00000.
21. Guerin O, Formento P, Lo Nigro C, Hofman P, Fischel JL, et al. (2008) Supra-additive antitumor effect of sunitinib malate (SU11248, sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol134 (1):: 51-57. 10.1007/s00432007-0247-4.
22. Cumashi A, Tinari N, Rossi C, Lattanzio R, Natoli C, et al. (2008) Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 270 (2): 229-233. 10.1016/j.canlet.2008.05.007.
23. Ortholan C, Durivault J, Hannoun-Levi JM, Guyot M, Bourcier C, et al. (2010) Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: A new paradigm for understanding the therapeutic effect of combined treatment. Eur J Cancer 46 (16):: 3022-3036. 10.1016/j.ejca.2010.07.021.
24. Kutikov A, Makhov P, Golovine K, Canter DJ, Sirohi M, et al. (2011) Interleukin-6: A potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer. Urology 78 (4):: 968.e7-968.11. 10.1016/j.urology.2011.07.1384.
25. Jeong CW, Yoon CY, Jeong SJ, Hong SK, Byun SS, et al. (2012) The role of hypoxia-inducible factor-1alpha and-2alpha in androgen insensitive prostate cancer cells. Urol Oncol. 10.1016/j.urolonc.2012.03.022.
26. Otto T, Rembrink K, Goepel M, Meyer-Schwickerath M, Rubben H, (1993) E-cadherin: A marker for differentiation and invasiveness in prostatic carcinoma. Urol Res 21 (5):: 359-362.
27. Ketola K, Hilvo M, Hyotylainen T, Vuoristo A, Ruskeepaa AL, et al. (2012) Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. Br J Cancer 106 (1)():: 99-106. 10.1038/bjc.2011.530.
28. Ketola K, Vuoristo A, Orešič M, Kallioniemi O, Iljin K, (2012) Monensin induced oxidative stress reduces prostate cancer cell migration and cancer stem cell population. In: Dr. Volodymyr Lushchak editor. Oxidative Stress and Diseases. InTech ISBN: 978-953-51-0552-7.
29. Harma V, Virtanen J, Makela R, Happonen A, Mpindi JP, et al. (2010) A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS One5 (5): e10431. 10.1371/journal.pone.0010431.
30. Dayyani F, Gallick GE, Logothetis CJ, Corn PG, (2011) Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst103 (22):: 1665-1675. 10.1093/jnci/djr362.
31. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, et al. (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A109 (8):: 2784-2789. 10.1073/pnas.1018866109.
32. Croker AK, Allan AL, (2011) Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDH(hi)CD44 (+) human breast cancer cells. Breast Cancer Res Treat. 10.1007/s10549-011-1692-y.
33. Marijon H, Dokmak S, Paradis V, Zappa M, Bieche I, et al. (2011) Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma. J Hepatol54 (5):: 1073-1078. 10.1016/j.jhep.2010.11.011.